AEGiS-PRn: PAMBEC Laboratories Inc. Unveils New Anti-AIDS Drug

Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.

PAMBEC Laboratories Inc. Unveils New Anti-AIDS Drug

PRNewswire - November 29, 2001

FORT COLLINS, Colo., Nov. 29 /PRNewswire/ -- PAMBEC Laboratories Inc., of Loveland, Colorado today announced the release of a new Anti-AIDS drug AIDFAREL(TM) using a new drug technology invented by the company. This new technology shows great promise in permanently stopping the human immunodeficiency virus-1 (HIV-1), which causes AIDS. The drug, soon to be delivered to the National Cancer Institute (NCI) for final cellular testing, works differently from all other Anti-AIDS drugs, whether synthesized or found in nature. Clinical trials of the drug will begin subsequent to the cellular test data having been reviewed by the Food and Drug Administration (FDA).

AIDFAREL(TM) inhibits both the replication and transcription of the integrated viral DNA known as a provirus by using the drug technology Binary Molecular DNA Clamp (BMC). The drug consists of two similar but distinct parts that can be "programmed" to bind to any specific Double Stranded DNA (dsDNA) sequence, in any gene. In CD4 T-cells infected with the HIV-1 virus, the drug is set to bind where the tat and rev genes overlap. Once bound to the specified dsDNA sequence, the two parts react with each other to become one molecule that surrounds the target DNA molecular sequence, completely preventing transcription and translation of that region, and shutting down all viral production permanently.

AIDFAREL(TM) is unique in that it only needs to be given three times over a one-month period, making the treatment process significantly less taxing for patients. Complete reconstitution of the immune system occurs within three to five weeks of the first intravenous injection of AIDFAREL(TM).

Binary Molecular DNA Clamp drug technology represents a promising new form of anti-retroviral chemotherapy, for both AIDS and other genetic disorders.

011129
PR011139

Copyright © 2001 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.PRNewswire.com.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .